1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Coral Laboratories Limited

Coral Laboratories Limited

BBSE:CORALAB
506.95
INR
-7.30
(-1.42%)
53.76EPS
11.72P/E
2.25BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
142.2
166.32
205.68
255.63
251.57
247.15
191.04
266.49
204.96
218.03
229.8
316.8
236.18
270.66
Basic EPS, GAAP
22.02
26.79
34.7
45.61
34.84
28.6
19.96
37.94
25.32
18.04
44.19
67.61
45.85
53.76
Free Cash Flow per Basic Share
2.32
-3.85
11.64
24.53
24.45
-10.35
-14.67
-1.2
1.5
30.01
-18.07
-11.66
-22.16
- -
Dividend per Share
- -
- -
- -
3.61
6.02
2.41
2.41
- -
- -
- -
- -
2
1.5
- -
Book Value per Share
141.57
165.35
196.44
305.54
325.63
318.45
323.77
382.48
436.81
433.29
496.83
563.19
585.33
- -
Tangible Book Value per Share
141.49
165.29
196.33
305.3
325.43
318.28
323.65
382.4
436.75
433.24
496.65
563
585.17
- -
Basic Weighted Avg Shares
4
4
4
4
4
4
4
4
4
4
4
4
4
4
Sales/Revenue/Turnover
508
594
735
913
899
883
683
952
732
779
821
1,132
844
967
Operating Margin (%)
17.28
16.46
20.07
23.84
15.34
11.92
5.01
14.56
8.5
2.09
17.37
21.75
15.65
16.73
Depreciation Expense
12
26
17
16
16
19
20
20
20
22
20
20
21
23
Net Income, GAAP
79
96
124
163
124
102
71
136
90
64
158
242
164
192
Effective Tax Rate (%)
20.69
21.62
28.76
33.66
31.05
34.11
21.79
23.04
23.7
21.65
23.84
25.61
29.13
27.08
Profit Margin (%)
15.49
16.11
16.87
17.84
13.85
11.57
10.45
14.24
12.35
8.27
19.23
21.34
19.41
19.86
Working Capital
287
381
466
550
521
656
707
1,011
1,053
1,117
1,290
1,516
1,497
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
506
591
702
1,092
1,163
1,138
1,157
1,366
1,561
1,548
1,775
2,012
2,091
- -
Return on Invested Capital (%)
14.68
13.78
16.04
15.61
8.29
5.95
2.24
7.88
3.47
0.8
6.21
8.68
4.29
- -
Return on Capital (%)
16.59
17.24
19.02
17.94
10.87
8.77
6.06
10.27
6
4.24
9.5
12.68
7.89
- -
Return on Common Equity (%)
16.72
17.46
19.18
18.17
11.04
8.88
6.22
10.74
6.18
4.15
9.5
12.76
7.98
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
43
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
1,567
1,324
2,251

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
1,770
- -
Cash, Cash Equivalents & STI
- -
307
- -
Accounts Receivable, Net
- -
294
- -
Inventories
- -
205
- -
Total Current Liabilities
- -
273
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
43
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.51%
9.07%
3.93%
Free Cash Flow
148.97%
314.36%
89.96%
Net Income, GAAP
15.36%
20.75%
-32.18%
Sales/Revenue/Turnover
3.88%
0.22%
-25.45%
Total Cash Common Dividend
- -
- -
-25%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
317
322
230
281
1,132
2026
188
190
216
265
844
2027
296
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
24.64
17.86
17.2
7.91
67.61
2026
7.18
16.29
7.77
14.62
45.85
2027
15.08
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
2
2026
- -
- -
- -
- -
1.5
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Girish Madanlal Dhameja
Full Time Employees
149
Sector
Health technology
Industry
Pharmaceuticals: other
Address
#3B, Patanwala Compound Mumbai MA India 400086
IPO Date
Mar 17, 1994
Website
corallab.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Coral Laboratories Limited is a pharmaceutical and healthcare company engaged in the manufacturing, marketing, and distribution of a diverse range of pharmaceutical formulations, active pharmaceutical ingredients (APIs), herbal products, and nutraceuticals. Its core products include prescription medicines, generic drugs, over-the-counter (OTC) healthcare products, and herbal supplements. The company operates primarily in India, serving domestic markets as well as select international markets. Founded in 1984 and headquartered in Mumbai, India, Coral Laboratories delivers comprehensive healthcare solutions encompassing cardiovascular, anti-infective, gastrointestinal, and respiratory therapeutic segments. The company manufactures branded and generic formulations across various dosage forms such as tablets, capsules, injectables, and syrups. Additionally, it offers contract manufacturing services and exports its products to multiple countries. Recent company developments within the last 1-2 years include strategic partnerships aimed at expanding product reach and capital infusion for growth initiatives. Coral Laboratories has undertaken efforts to strengthen its portfolio by launching new products in specialty therapeutic areas and enhancing production capabilities with modernized manufacturing facilities. These moves reflect a strategic focus on expanding domestic market share and exploring international business opportunities. Coral Laboratories operates within the pharmaceutical industry, targeting healthcare providers, pharmacies, hospitals, and wellness retailers. The company maintains a network of subsidiaries and collaborations to support research, development, and marketing efforts. As a listed entity on the Bombay Stock Exchange (ticker: CORALAB.BO), Coral Laboratories emphasizes adherence to regulatory standards and quality compliance in all its operations.